# Estrogen inhibits the vascular injury response in estrogen receptor $\beta$ -deficient female mice

Richard H. Karas<sup>\*†</sup>, Jeffrey B. Hodgin<sup>‡</sup>, Moon Kwoun<sup>∗§</sup>, John H. Krege<sup>‡</sup>, Mark Aronovitz<sup>\*†</sup>, William Mackey<sup>∗§</sup>, Jan Åke Gustafsson<sup>¶</sup>, Kenneth S. Korach<sup>∥</sup>, Oliver Smithies<sup>‡</sup>, and Michael E. Mendelsohn<sup>\*†\*\*</sup>

\*Molecular Cardiology Research Institute, New England Medical Center Hospitals, and Departments of <sup>†</sup>Medicine and <sup>§</sup>Vascular Surgery, Tufts University School of Medicine, Boston, MA 02111; <sup>‡</sup>Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27709; <sup>§</sup>National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709; and <sup>¶</sup>Department of Medical Nutrition, Karolinska Institute, S-141-86 Huddinge, Sweden

Edited by Donald W. Pfaff, The Rockefeller University, New York, NY, and approved November 2, 1999 (received for review September 16, 1999)


The protective effects of estrogen in the cardiovascular system result from both systemic effects and direct actions of the hormone on the vasculature. Two estrogen receptors have been identified,  $ER\alpha$  and ERβ. We demonstrated previously that estrogen inhibits the response to vascular injury in both wild-type and  $ER\alpha$ -deficient mice, and that  $ER\beta$  is expressed in the blood vessels of each, suggesting a role for  $ER\beta$  in the vascular protective effects of estrogen. In the present study, we examined the effect of estrogen administration on mouse carotid arterial injury in ER<sub>β</sub>-deficient mice. Surprisingly, in ovariectomized female wild-type and ER $\beta$  knockout mice, 17 $\beta$ -estradiol markedly and equally inhibited the increase in vascular medial area and the proliferation of vascular smooth muscle cells after vascular injury. These data demonstrate that  $ER\beta$  is not required for estrogenmediated inhibition of the response to vascular injury, and suggest that either of the two known estrogen receptors is sufficient to protect against vascular injury, or that another unidentified estrogen receptor mediates the vascular protective effects of estrogen.

### $17\beta$ -estradiol | vascular smooth muscle

he cardiovascular protective effects of estrogen are well established, and the direct effects of the hormone on vascular tissues are now well recognized (1, 2). Using a model of carotid arterial injury in a mouse, we have shown previously that administration of physiologic levels of  $17\beta$ -estradiol (E2) completely inhibits the vascular injury response in ovariectomized female wild-type (w.t.) mice (3, 4). Subsequent studies demonstrated that E2 continues to protect against vascular injury in ER $\alpha$  knockout mice ( $\alpha$ ERKO) (4), indicating that estrogen can inhibit the vascular injury response by an ER $\alpha$ -independent pathway. Another estrogen receptor, termed ER $\beta$ , was identified recently (5), suggesting the possibility that ER $\beta$  mediates the protective effects of E2 on the vasculature. Studies demonstrating that  $ER\beta$  is expressed in vascular cells and tissues (4, 6–11), and, in contrast to ER $\alpha$ , that ER $\beta$  mRNA expression increases in vascular endothelial and smooth muscle cells after vascular injury (11, 12), prompted widespread speculation that ER $\beta$  may place a central role in mediating the cardiovascular effects of E2 (10, 13, 14). To test directly the hypothesis that  $ER\beta$  mediates the vasoprotective effects of estrogen, we have now developed knockout mice in which the ER $\beta$  gene is disrupted by gene targeting ( $\beta$ ERKO) (15). In the present study, we examine the effect of estrogen on the response to vascular injury in these βERKO mice.

## Methods

**Animals.** The  $\beta$ ERKO mice were generated by targeted disruption of exon three of the ER $\beta$  gene as described (15). The  $\beta$ ERKO mice are normal in appearance, but the females are subfertile because of impaired ovarian function (15). For vascular injury studies, 3- to 4-month-old F<sub>2</sub> littermates bred from heterozygote matings of F<sub>1</sub> animals (129 × C57BL/6J) were used. The mice were fed a normal diet *ad libitum*, as previously described (3, 4).



**Fig. 1.** Design of the carotid artery injury study. All animals were ovariectomized, and then allowed to recover for 7–10 days. Estrogen-containing (E2) or vehicle-containing (V) pellets were implanted s.c. one week before the animals underwent unilateral carotid injury and implantation of an osmotic minipump containing BrdU. On day 14 after injury, the animals were anesthetized and killed; both carotid arteries were perfusion-fixed, harvested, and embedded in paraffin. Vessels were then sectioned transversely and stained to allow morphometric and immunohistochemical analysis of the response to injury. Further details of the procedure have been published previously (3, 4).

**Carotid Artery Injury.** Ovariectomized F<sub>2</sub> female mice (30 w.t. and 27  $\beta$ ERKO) underwent unilateral carotid artery injury under the protocol described in detail previously (3, 4) (Fig. 1). Briefly, w.t. and  $\beta$ ERKO mice were ovariectomized, allowed to recover, and then randomized to receive either placebo pellets (-E2) or E2-containing pellets (+E2) (Innovation Research, Sarasota, FL) to reestablish circulating physiological levels of E2 (3, 4). One week after pellet implantation, endothelial denudation vascular injury was produced by intraluminal introduction of a thin wire into the left common carotid artery. Two weeks after injury, the animals were anesthetized and killed and the uninjured and injured vessels were harvested.

**Morphometry and Immunohistochemistry.** The response to vascular injury was evaluated by measuring the medial area and by immunohistologic assessment of vascular smooth muscle cell (VSMC) proliferation (BrdU incorporation). Parallel sections from all 114 carotid arteries were stained for hematoxylin/eosin and for elastin, and area measurements were made by using a computerized morphometric analysis system on the elastin-stained sections (3, 4). For each animal, two sections were analyzed, and the medial area measurements were averaged. BrdU-labeled cells were identified by immunostaining, and counted, as described (3, 4). All measure

MEDICAL SCIENCES

This paper was submitted directly (Track II) to the PNAS office.

Abbreviations: E2, 17 $\beta$ -estradiol; ER, estrogen receptor;  $\beta$ ERKO, mice with the ER $\beta$  gene disrupted by gene targeting; RT, reverse transcription; VSMC, vascular smooth muscle cell; w.t., wild type.

<sup>\*\*</sup>To whom reprint requests should be addressed at: Molecular Cardiology Research Institute, New England Medical Center Hospitals, Inc., 750 Washington Street, #80, Boston, MA 02111. E-mail: mmendelsohn@lifespan.org.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.




Fig. 2. Reverse Transcriptase-PCR analysis of  $ER\alpha$  and  $ER\beta$  expression in w.t. and  $\beta$ ERKO aortae. PCR was performed by using either ER $\alpha$ - or ER $\beta$ -specific primers on the product of an RT reaction with RNA derived from w.t. (W) or  $\beta$ ERKO (K) aortae, or w.t. mouse uterus (U). The RT reaction was carried out in the absence (-) or presence (+) of reverse transcriptase. Primer pairs were selected to produce PCR products of 240 bp (ER $\beta$ ) or 611 bp (ER $\alpha$ ). The PCR products were then separated by agarose gel electrophoresis. A 100-bp DNA ladder (leftmost lane) is provided as a comparison for evaluating the size of the PCR products.


ments were made by two independent observers fully blinded to treatment. To distinguish between different vascular cell types, immunostaining was also performed on parallel carotid artery sections with endothelial cell-specific factor VIII-related antigen (Sigma) and VSMC-specific  $\alpha$ -actin antibodies (Sigma) (3, 4).

Reverse Transcriptase-PCR. Random hexamer-primed reverse transcription (RT) reactions were carried out with 1.25  $\mu$ g of total RNA (TriReagent, Sigma), derived from the aortae of w.t. or βERKO mice, or from w.t. uterus. The primers for PCR included: (i) ER $\beta$ -specific forward primers, 5'-25 (base pairs 25–46) and 5'-38 (base pairs 38–59); (ii) ER $\beta$ -specific reverse primers, 3'-299 (base pairs 299-278) and 3'-798 (base pairs 798-787); (iii) ERα-specific forward primers, 5'-506 (base pairs 506-526) and 5'-536 (base pairs 536–556); and (iv) ER $\alpha$ -specific reverse primers, 3'-1185 (base pairs 1185-1155) and 3'-1147 (base pairs 1147-1127). These primers are based on the published coding sequences for murine  $ER\alpha$ (16) and ER $\beta$  (5). The specificity of the primers was confirmed by PCR with plasmids containing ER $\alpha$  and ER $\beta$  cDNAs. Negative controls, in which the RT enzyme was omitted, were included in all experiments. The following PCR protocol was employed: 94°C for 5 min, followed by 32 cycles of 94°C for 1 min, 50°C for 1 min, 72°C for 1 min, and a final 5-min extension at 72°C. In all cases, nested PCR was then carried out on the initial PCR product by using receptor-specific internal primers.


Statistical Analyses. For all analyses, within-group differences were assessed with one-factor ANOVA; post hoc comparisons were tested with the Student–Newman–Keuls test. P < 0.05 was considered significant.


# Results

The expression of ER $\alpha$  and ER $\beta$  mRNA in the vasculature of the w.t. and BERKO mice was investigated by using reverse transcriptase-PCR. ERß mRNA was expressed in low abundance in



Uninj Inj,-E2 Inj,+E2





the vasculature of the w.t. mice (Fig. 2), confirming our previous findings (4, 11, 12). As expected, ER $\beta$  mRNA was not detectable in the  $\beta$ ERKO vessels. Furthermore, disruption of the ER $\beta$  gene in the  $\beta$ ERKO mice had no effect on the level of vascular expression of ER $\alpha$  mRNA (Fig. 2).

The response to vascular injury in the w.t. and BERKO mice was quantified by measuring both the carotid medial area and the VSMC proliferation 2 weeks after endothelial denudation (3, 4). There were no differences observed in the medial areas of the uninjured vessels of the w.t. and BERKO mice. In the w.t. mice, injury induced an increase in medial area from  $16.1 \pm 0.6 \times 10^{-3}$ mm<sup>2</sup> in the w.t. uninjured to  $20.0 \pm 0.9 \times 10^{-3}$  mm<sup>2</sup> in the w.t. injured -E2; P < 0.05 (Fig. 3). E2 replacement inhibited the increase in the medial area after injury in the w.t. mice to a value indistinguishable from that of the uninjured vessels (17.8  $\pm$  0.6  $\times$  $10^{-3}$  mm<sup>2</sup>; P < 0.05 vs. w.t. injured -E2). In the  $\beta$ ERKO mice, injury also caused a significant increase in carotid medial area (from  $16.8 \pm 0.6 \times 10^{-3}$  mm<sup>2</sup> in the  $\beta$ ERKO uninjured to  $19.8 \pm 0.6 \times$  $10^{-3}$  mm<sup>2</sup> in  $\beta$ ERKO injured -E2; P < 0.05 for injured vs. uninjured; see Fig. 3). Just as in the w.t. mice, E2 treatment prevented the increase in medial area after injury in the  $\beta$ ERKO animals (16.8  $\pm$  0.6  $\times$  10<sup>-3</sup> mm<sup>2</sup>  $\beta$ ERKO injured +E2; P < 0.05for injured +E2 vs. injured -E2; P is not significant for injured +E2 vs. uninjured). There were no significant differences between the w.t. and BERKO mice for either the increase in carotid medial area after injury or for suppression of this response by E2 treatment.

The extent of vascular cell proliferation was assessed 14 days after vascular injury. BrdU-labeled cells were rarely detected in the uninjured arteries of the w.t. and the  $\beta$ ERKO mice (average of <1 labeled cell per vessel for both w.t. and

**Fig. 4.** Medial smooth muscle cell proliferation in uninjured and injured w.t. and  $\beta$ ERKO mouse carotid arteries treated with vehicle or E2. (*A–F*) Representative segments of BrdU-stained carotid artery sections are shown (×400). The number of BrdU-positive smooth muscle cells for each section is listed. All BrdU counts were made for complete sections. (*A*) Wild-type, uninjured (Unij; 0 cells). (*B*) Wild-type injured, vehicle-treated (Inj, –E2; 58 cells). (*C*) Wild-type, injured, E2-treated (Inj, +E2; 29 cells). (*D*)  $\beta$ ERKO (Uninj; 0 cells). (*E*) BERKO (Inj, –E2; 45 cells). (*F*)  $\beta$ ERKO (Inj, + E2; 17 cells). (*G*) Summary medial VSMC BrdU labeling data for all w.t. and  $\beta$ ERKO mice. The number of BrdU-labeled cells did not differ between the w.t. and  $\beta$ ERKO mice in the injured, vehicle-treated groups (59 ± 10 cells per section vs. 46 ± 10 cells per section, respectively) or in the injured E2-treated groups (27 ± 5 cells per section vs. 15 ± 3 cells per section, respectively). \*, *P* < 0.05, compared with both uninjured, and injured, estrogentreated groups within the same genotype; \*\*, *P* < 0.05, compared with uninjured within the same genotype.

 $\beta$ ERKO). As shown in Fig. 4, carotid injury induced a marked increase in BrdU-labeled VSMCs in w.t. animals (to  $59 \pm 10$ cells per section; P < 0.05 for injured, -E2 vs. uninjured). This increase in VSMC proliferation was attenuated by E2 treatment (to 27  $\pm$  5 cells per section; P < 0.05 for injured +E2 vs. injured -E2). In the  $\beta$ ERKO mice, the same pattern was seen; injury caused substantial VSMC proliferation in placebotreated mice (to  $46 \pm 10$  cells per section; P < 0.05 for  $\beta$ ERKO injured -E2 vs. BERKO uninjured), and E2 again inhibited the injury-induced proliferation of VSMC in the BERKO mice (to  $15 \pm 3$  cells per section; P < 0.05 for  $\beta$ ERKO injured, +E2 vs.  $\beta$ ERKO injured -E2; see Fig. 4). There were no significant differences in the amount of VSMC proliferation between the w.t. and  $\beta$ ERKO animals within each treatment group. Thus, for this second independent measure of vascular injury response, E2 proved equally protective in the w.t. and  $\beta$ ERKO mice. A similar increase in the extent of endothelial cell proliferation 14 days after injury was seen in both the placebotreated w.t. group (38  $\pm$  3 cells per section; P < 0.05 for injured vs. uninjured) and  $\beta$ ERKO (34 ± 3 cells per section; P < 0.05for injured vs. uninjured) carotid arteries. The extent of endothelial cell labeling was also similar for the w.t. and  $\beta$ ERKO mice treated with E2 (39 ± 2 and 37 ± 2 cells per section, respectively). Thus, there were no differences in the extent of endothelial cell proliferation at 14 days after injury between any of the groups (P is not significant for all comparisons). As shown previously (3, 4), only a minority of vessels developed a detectable neointimal response after injury (9 of 57 animals or 16%). Thrombosis was observed in only 1 of the 57 injured vessels.

# Discussion

The effects of estrogen on the cardiovascular system are diverse; they include indirect effects on systemic factors as well as direct effects on the vasculature (for review, see refs. 2, 17, and 18). The direct effects of E2 on the vasculature include rapid effects on vasomotor tone (19-22), and longer-term effects on atherosclerosis (3, 4, 17, 18, 23-26) and vascular cell proliferation and migration (17, 18, 27-32). The longer-term effects of estrogens result from alterations in gene expression, and are believed to be mediated by estrogen receptors, which are ligand-activated transcription factors (33, 34). The data presented here show that E2 inhibits equally well the response to vascular injury in ER<sub>β</sub>-deficient mice and their littermate w.t. controls. We have previously shown that estrogen inhibits the response to carotid artery injury in w.t. mice (3, 4) and in mice devoid of ER $\alpha$  (4), demonstrating that this vasoprotective effect of estrogen also does not require ER $\alpha$ . After the identification of ER $\beta$ , studies demonstrated that ER $\beta$  is expressed in the heart (refs. 35, 36, and unpublished observations) as well as in the vasculature (4, 11, 36), and that ER $\beta$ , but not ER $\alpha$ , mRNA levels are markedly increased in vascular endothelial cells and in VSMCs after vascular injury in male rats (11, 12). These data suggested to many researchers that  $ER\beta$  may mediate the vasoprotective effects of E2 (10, 13, 14). Several other observations also support different functional roles for ER $\beta$  and ER $\alpha$ . Although ER $\beta$  and ER $\alpha$  are highly homologous in some domains (e.g., the DNAbinding domains), other regions of the proteins (e.g., the N terminus) share little or no homology (5). In addition, the two receptors differ with respect to their patterns of cell-specific tissue expression (35–38), ligand-binding affinities (35, 39), and gene targets (refs. 40, 41, and unpublished observations), further

- 1. Grady, D., Rubin, S. M., Petitti, D. B., Fox, C. S., Black, D., Ettinger, B., Ernster, V. L. & Cummings, S. R. (1992) Ann. Intern. Med. 117, 1016-1037.
- 2. Mendelsohn, M. E. & Karas, R. H. (1999) N. Engl. J. Med. 340, 1801-1811.
- 3. Sullivan, T. R., Jr., Karas, R. H., Aronovitz, M., Faller, G. T., Ziar, J. P., Smith, J. J., O'Donnell, T. F., Jr., & Mendelsohn, M. E. (1995) J. Clin. Invest. 96, 2482-2488
- 4. Iafrati, M. D., Karas, R. H., Aronovitz, M., Kim, S., Sullivan, T. R., Jr., Lubhan, D. B., O'Donnell, T. F., Jr., Korach, K. S. & Mendelsohn, M. E. (1997) Nat. Med. 3. 545-548
- 5. Kuiper, G. G. J. M., Enmark, E., Pelto-Huikko, M., Nilsson, S. & Gustafsson, J. Å. (1996) Proc. Natl. Acad. Sci. USA 93, 5925-5930.
- 6. Losordo, D. W., Kearney, M., Kim, E. A., Jekanowski, J. & Isner, J. M. (1994) Circulation 89, 1501-1510.
- 7. Karas, R. H., Patterson, B. L. & Mendelsohn, M. E. (1994) Circulation 89, 1943-1950
- 8. Venkov, C. D., Rankin, A. B. & Vaughan, D. E. (1996) Circulation 94, 727-733.
- 9. Caulin-Glaser, T., García-Cardeña, G., Sarrel, P., Sessa, W. C. & Bender, J. R. (1997) Circ. Res. 81, 885-892.
- 10. Register, T. C. & Adams, M. R. (1998) J. Steroid Biochem. Mol. Biol. 64, 187-191.
- 11. Lindner, V., Kim, S. K., Karas, R. H., Kuiper, G. G. J. M., Gustafsson, J. Å. & Mendelsohn, M. E. (1998) Circ. Res. 83, 224-229.
- 12. Makela, S., Savolainen, H., Aavik, E., Myllarniemi, M., Strauss, L., Taskinen, E., Gustafsson, J.-Å. & Hayry, P. (1999) Proc. Natl. Acad. Sci. USA 96, 7077-7082. 13. Gustafsson, J. Å. (1997) Nat. Med. 3, 493-494.
- 14. Katzenellenbogen, B. S. & Korach, K. S. (1997) Endocrinology 138, 861-862.
- 15. Krege, J. H., Hodgin, J. B., Couse, J. F., Enmark, E., Warner, M., Mahler, J. F., Sar, M., Korach, K. S., Gustafsson, J.-Å. & Smithies, O. (1998) Proc. Natl. Acad. Sci. USA 95, 15677-15682
- 16. White, R., Lees, J. A., Needham, M., Ham, J. & Parker, M. (1987) Mol. Endocrinol. 1. 735-744.
- 17. Mendelsohn, M. E. & Karas, R. H. (1994) Curr. Opin. Cardiol. 9, 619-626.
- 18. Farhat, M. Y., Lavigne, M. C. & Ramwell, P. W. (1996) FASEB J. 10, 615-624.
- 19. Guetta, V., Quyyumi, A. A., Prasad, A., Panza, J. A., Waclawiw, M. & Cannon, R. O., III (1997) Circulation 96, 2795-2801.
- 20. Reis, S. E., Gloth, S. T., Blumenthal, R. S., Resar, J. R., Zacur, H. A., Gerstenblith, G. & Brinker, J. A. (1994) Circulation 89, 52-60.
- 21. Gilligan, D. M., Quyyumi, A. A., Cannon, R. O., III, Johnson, G. B. & Schenke, W. H. (1994) Circulation 89, 2545-2551.

supporting a potential role in the cardiovascular system for  $ER\beta$ that is distinct from that for  $ER\alpha$ .

The data presented here demonstrate equivalent inhibition by estrogen of the response to vascular injury in βERKO and w.t. mice, and show that  $ER\beta$  is not required for estrogen-mediated vasoprotection in this model. One explanation for these findings is that  $ER\alpha$ and ER $\beta$  play redundant roles in mediating vascular protection by estrogen, such that the presence of either ER $\alpha$  or ER $\beta$  is sufficient to achieve vascular protection. Such functional redundancy between ER $\alpha$  and ER $\beta$  might reflect the fundamental biological importance of the vasoprotective effect of estrogen. An alternative to this hypothesis is that another, still unidentified estrogen receptor (i.e., "ER $\gamma$ ") mediates the vasoprotective effects of estrogen. Differentiation of these two hypotheses will be addressed directly by studying the effects of estrogen on the response to injury in mice lacking both known estrogen receptors, when they become available. In summary, the present study shows that arterial injury leads to similar increases in carotid medial area and smooth muscle cell proliferation in w.t. and  $\beta$ ERKO mice, and that these measures of vascular injury are inhibited significantly and to the same degree by E2 in both ER $\beta$ -deficient animals and their w.t. littermates. Our results suggest that either of the two known estrogen receptors, ER $\alpha$  or ER $\beta$ , is sufficient to protect against vascular injury, or that an unidentified receptor for estrogen exists that mediates the vasoprotective effects of estrogen.

The authors acknowledge the technical assistance of Flore Celestin. We also thank Patricia Griffiths and Christine Robertson for expert preparation of the manuscript. This work was supported in part by National Institutes of Health Grants RO1 HL61298 to R.H.K. and RO1 HL56069 and HL59953 to M.E.M.; M.E.M. is an Established Investigator of the American Heart Association.

- 22. Williams, J. K., Adams, M. R., Herrington, D. M. & Clarkson, T. B. (1992) J. Am. Coll. Cardiol. 20, 452-457.
- 23. Adams, M. R., Kaplan, J. R., Manuck, S. B., Koritnik, D. R., Parks, J. S., Wolfe, M. S. & Clarkson, T. B. (1990) Arteriosclerosis 10, 1051-1057.
- 24. Haarbo, J., Leth-Espensen, P., Strander, S. & Cristiansen, C. (1991) J. Clin. Invest. 87, 1274-1279.
- 25. Chen, S. J., Li, H. B., Durand, J., Oparil, S. & Chen, Y. F. (1996) Circulation 93, 577-584
- 26. Bourassa, P. A. K., Milos, P. M., Gaynor, B. J., Breslow, J. L. & Aiello, R. J. (1996) Proc. Natl. Acad. Sci. USA 93, 10022-10027.
- 27. Fischer-Dzoga, K., Wissler, R. & Vesselinovitch, D. (1983) Exp. Mol. Pathol. 39, 355-363.
- 28. Farhat, M. Y., Vargas, R., Dingaan, B. & Ramwell, P. W. (1992) Br. J. Pharmacol. 107, 679-683
- 29. Moraghan, T., Antoniucci, D. M., Grenert, J. P., Sieck, G. C., Johnson, C., Miller, V. M. & Fitzpatrick, L. A. (1996) Endocrinology 137, 5174–5177.
- 30. Kolodgie, F. D., Jacob, A., Wilson, P. S., Carlson, G. C., Farb, A., Verma, A. & Virmani, R. (1996) Am. J. Pathol. 148, 969-976.
- 31. Johns, A., Freay, A. D., Fraser, W., Korach, K. S. & Rubanyi, G. M. (1996) Endocrinology 137, 4511-4513.
- 32. Morales, D. E., McGowan, K. A., Grant, D. S., Maheshwari, S., Bhartiya, D., Cid, M. C., Kleinman, H. K. & Schnaper, W. (1995) Circulation 91, 755-763.
- 33. Green, S., Walter, P., Kumar, V., Krust, A., Bornert, J.-M., Argos, P. & Chambon, P. (1986) Nature (London) 320, 134-139.
- 34. Evans, R. M. (1988) Science 240, 889-895.
- 35. Kuiper, G. G. J. M., Carlsson, B., Grandien, K., Enmark, E., Häggblad, J., Nilsson, S. & Gustafsson, J. Å. (1997) Endocrinology 138, 863-870.
- 36. Couse, J. F., Lindzey, J., Grandien, K., Gustafsson, J. Å. & Korach, K. S. (1997) Endocrinology 138, 4613-4621.
- 37. Saunders, P. T. K., Maguire, S. M., Gaughan, J. & Millar, M. R. (1997) J. Endocrinol. 154, R13-R16.
- 38. Mosselman, S., Polman, J. & Dijkema, R. (1996) FEBS Lett. 392, 49-53.
- 39. Barkhem, T., Carlsson, B., Nilsson, Y., Enmark, E., Gustafsson, J. Å. & Nilsson,
- S. (1998) Mol. Pharmacol. 54, 105-112. 40. Paech, K., Webb, P., Kuiper, G. G. J. M., Nilsson, S., Gustafsson, J. Å., Kushner, P. J. & Scanlan, T. S. (1997) Science 277, 1508-1510.
- 41. Kuiper, G. G. J. M. & Gustafsson, J. Å. (1997) FEBS Lett. 410, 87-90.